Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2023

ESMO-TAT-2023-1000x250

The home of Phase 1 in oncology

The ESMO Targeted Anticancer Therapies Congress 2023 will be back to Paris in March 2023, for another exciting edition, offering participants a glimpse of the future of targeted anticancer therapies.

ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.

Stakeholders from academia and industry will discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.

Scientific Co-Chairs

  • Ruth Plummer, Newcastle upon Tyne, UK
  • Lillian Siu, Toronto, ON, Canada
  • Anastasios Stathis, Bellinzona, Switzerland

Organisation

ESMO Head Office Via Ginevra 4, 6900 Lugano Switzerland meetings@esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.